This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
The course learning objectives are as follows:
• Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
• Develop individualized treatment regimens for patients with retinal disorders, with a concentration on those with AMD.
• Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.
• Explain the mechanism of action of these newer compounds and how they differ from those currently available.
This educational activity is provided by Evolve Medical Education LLC (Evolve).
Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
David A. Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology University of South Florida
Morsani College of Medicine
Director of Research, Retina Vitreous Associates of Florida
Tampa, Florida
Christina Y. Weng, MD, MBA
Associate Professor of Ophthalmology
Fellowship Program Director
Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, Texas
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:
David A. Eichenbaum, MD, FAAO has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s List: Allergan, Bayer, DORC, EyePoint, Genentech and Novartis.
Christina Y. Weng, MD, MBA has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals and REGENXBIO. The
Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Genentech, a member of the Roche Group.
